A light blue background featuring a large, semi-transparent DNA double helix structure that spirals from the top right towards the bottom left.

**ydbio**

 **Nasdaq : YDES**

**Investor Presentation**  
**October 2025**

# Forward-looking Statements

This presentation contains forward-looking statements. All statements contained in this presentation other than statements of historical fact, including statements regarding our future results of operations and financial position, our business strategy and plans, and our objectives for future operations, are forward-looking statements. These forward-looking statements relate to events that involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from those expressed or implied by these statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in the “Risk Factors” section of the Company’s final prospectus filed with the U.S. Securities and Exchange Commission on July 18, 2025 (the “Final Prospectus”). Moreover, we operate in a very competitive and rapidly changing environment.

New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in the Final Prospectus may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. Thus, you should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, we undertake no duty to update any of these forward-looking statements after the date of the Presentation or to conform these statements to actual results or revised expectations.

The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any projections or modeling or any other information contained herein. Any data on past performance or modeling contained herein is not an indication as to future performance. YD Bio Limited assumes no obligation to update the information in this presentation.

ydbio



 Nasdaq



## **MISSION**

We are driven to transform healthcare through cutting-edge biotechnology. Our mission is to develop innovative solutions that not only advance science but meaningfully improve lives around the world.



## **VISION**

We envision a future where early cancer detection and regenerative therapies redefine patient care. Our goal is to deliver breakthrough outcomes and revolutionize how medical treatments are accessed and experienced globally. We are improving lives and offering strong returns for investors in high growth health markets.



## **VALUES**

Our values are the foundation of everything we do - guiding our science, our partnerships, and our promise to patients.

**Innovation**

**Excellence**

**Patient-Centered**

**Integrity**

**Collaboration**



**YD Bio is a biotechnology company pioneering next-generation solutions in cancer detection, regenerative medicine, and clinical innovation.**



# Company History

A decade of scientific innovation, global partnerships, and strategic expansion into breakthrough therapies.



## 2013–2015

### Foundation & Global Partnerships

#### Pharmacy & Supplement Origins

Established to manage clinical trial drugs, and develop targeted nutritional supplements.

#### Global Expansion

Became a clinical trial supplier to leading pharmaceutical companies.

## 2024- Present

### Breakthroughs in Exosome Innovation

#### Exosome R&D Partnership

Partnered with 3D Global Biotech Inc. to pioneer stem cell-derived exosome solutions for eyecare.

## 2024–Present

### New Platforms & Market Entry

#### Cancer Detection Platform

Partnered with EG Biomed to launch a U.S.-based lab (Seattle, WA) focused on DNA methylation diagnostics, accelerating our entry into early cancer detection.



# Our Key Partners

We Leverage Deep Scientific Alliances to Accelerate Growth



EG BIOMED

**EG Biomed** is a pioneering biotechnology company specializing in early **cancer detection/monitoring** by leveraging advanced molecular technologies, such as **DNA methylation analysis**.

20-year contract term starting in 2024.

## TECHNOLOGY FOCUS

- Non-invasive blood tests using cfDNA methylation analysis for early cancer detection/monitoring, including pancreatic, breast, and other cancers.
- cfDNA is used to detect tumor-derived DNA in blood, enabling early cancer detection, cancer progression monitoring, and post-treatment evaluation.



**Ruo-Kai Lin, PhD.**  
Chief R&D Officer,  
EG Biomed

Dr. Ruo-Kai Lin is a renowned expert in pharmacognosy and epigenetics, with extensive experience in academia and research. Currently, she serves as a Professor at the Graduate Institute of Pharmacognosy at Taipei Medical University, where she has been an active faculty member since 2010, where she has contributed significantly to biotechnology research and pharmacological studies.

### Educational Background

- Ph.D., Department of Life Sciences, National Taiwan Normal University
- Bachelor, Department of Nursing, College of Medicine, National Cheng-Kung University



**3D Global Biotech** is a leading biotechnology company specializing in the development of **regenerative medicine, exosome-based therapies, and medical devices**.

20-year contract from launch of relevant products.

## TECHNOLOGY FOCUS

- **Cell Culture and Exosome Technology:** Licensed technologies include *human limbal cell culture methods, cell bank construction, exosome purification, and exosome production*.
- Applications target treatments for *eye diseases, such as dry eye disease and corneal repair*, by utilizing mesenchymal stem cells (MSCs) and exosomes.



**Keng-Liang Ou, PhD.**  
Chairman,  
3D Global Biotech

Dr. Ou's experience in both academia and industry has given him a unique perspective on the distinct focuses of each. He has observed that academia seeks divergence in research, while industry thrives on convergence and consensus-building. He believes that the gap between research and application can be bridged through "translation," the process by which academic discoveries are converted into practical, market-ready solutions. He emphasizes that the regulatory framework should precede product development to ensure the commercialization of biomedicine.

### Educational Background

- PhD in Medicine, Osaka Medical University, Japan
- PhD in Mechanical Engineering, National Chiao Tung University

# Our Competitive Advantage

Our competitive edge is built on proven drug development capabilities, strategic global alliances, and a fully certified quality infrastructure trusted by leading pharmaceutical partners.



## DEVELOPMENT EXPERTISE

Proven ability to develop and market new drugs and products



## STRATEGIC PARTNERSHIPS

Established partner alliances to advance innovation



EG BIOMED



## PHARMA ALLIANCES

Strong business relationships with leading pharmaceutical companies



## QUALITY CERTIFIED

Full-scale and accredited testing system



# Credibility Backed by Recognition

Together with our partners 3D Global Biotech and EG Biomed, our work is validated by the experts who matter - from prestigious awards to peer-reviewed publications and industry certifications.

## **PATENTS GLOBALLY**

**11** LICENSED  
PATENTS

**12** PENDING  
PATENTS

## **AWARDS GLOBALLY**

**17** AWARDS & PUBLICATIONS

## **CERTIFICATIONS GLOBALLY**

**3** INDUSTRY CERTIFICATIONS

# Our Core Offerings

Transformative Technologies Across Diagnostics, Therapeutics & Wellness.

## U.S. Market



### CANCER DETECTION + MONITORING

YD Bio and EG BioMed offer non-invasive, highly accurate cancer detection solutions that enable earlier intervention and better patient outcomes.


- **20-year licensed patent** for proprietary cancer detection platform
- **Pancreatic cancer blood test** offered as a Laboratory Developed Test through our CAP-accredited, CLIA-certified laboratory
- **Breast cancer** monitoring test currently in clinical trials, with promising preclinical results



### EYE CARE

In partnership with 3D Global Biotech, we offer FDA-cleared devices and are developing exosome-based therapies and to improve ocular health and patient comfort.

- **20-year patent license** for limbal stem cell exosome technology
- **FDA 510(k)-cleared** Exovisse daily contact lenses for advanced comfort
- **FDA OTC Monograph M018 compliant** solution for tissue hydration in biomedical use



### DISTRIBUTION OF CLINICAL TRIAL DRUGS

We are a trusted partner to top pharma companies

- **Global Reach** – Support for multi-region and international studies
- **High-Quality Standards** – GMP-compliant sourcing, handling, and packaging
- **Tailored Solutions** – Customized logistics and regulatory support for trial-specific needs



### HEALTH SUPPLEMENTS

We offer science-backed supplements that support overall wellness

- **Targeted formulas** – Addressing key demographic concerns
- **Backed by Science** – Developed using evidence-based research
- **High-Quality Standards** – Manufactured under strict GMP protocols for consistency and safety

# Our Active Investigational New Drugs & In Vitro Diagnostic Pipeline

We are developing breakthrough solutions to transform patient outcomes - DNA methylation tests to detect cancer earlier and limbal stem cell exosome therapies to restore ocular hydration and reduce inflammation - both moving through robust research and clinical pipelines.

## EG BioMed - DNA Methylation Cancer Screening Tests Pipeline

Cancer Type / Application	Clinical Study in Asia	Clinical Study in US (research)	Breakthrough Device Program	Final Regulatory Approval (IVD) and Commercial Launch
Pancreatic Cancer Detection Test	▶			

Cancer Type / Application	Clinical Study (research)	Clinical Validation in Asia (confirmation)	De Novo Request	Clinical Validation in US (confirmation)	De Novo Submission	Final Regulatory Approval (IVD) and Commercial Launch
Breast Cancer Monitoring Test	▶					

## 3D Global Biotech - Limbal Stem Cell Exosome Therapeutics Pipeline

Technology / Application	Discovery	Preclinical	IND Filing	Phase 1	Phase 2	Phase 3	Final Regulatory Approval (BLA Application) and Commercial Launch
LSC Exosome Eye Drops	▶						
LSC Exosome Eye Injection	▶						

# Our Active Services & Product Pipeline

In the U.S, we currently provide commercially available laboratory-developed cancer detection tests through our partner CAP-accredited, CLIA-certified laboratory, along with established eye care products including artificial tears and contact lenses, while continuing to advance additional diagnostic tests through our development pipeline.

## Laboratory-Developed Test (LDT) Portfolio

Cancer Type / Application	Status
<b>Pancreatic Cancer Detection Test</b>	Available through our CAP-accredited, CLIA-certified laboratory
<b>Breast Cancer Monitoring Test</b>	Available through our CAP-accredited, CLIA-certified laboratory
<b>Colorectal Cancer Detection Test</b>	Available through our CAP-accredited, CLIA-certified laboratory
<b>GI Cancers Detection (pancreas, liver, colorectum)</b>	In Pipeline

## Eye Care Portfolio

Product	Status
<b>Artificial Tears</b>	Commercially Available
<b>Contact Lenses</b>	Commercially Available



# **Our Pipeline, Capabilities and Key Products**

# Pancreatic Cancer Detection

YD Bio's early detection platform uses non-invasive, biomarker-driven liquid biopsy technology to identify pancreatic cancer at its earliest stages, enabling earlier intervention and improving patient outcomes.

## THE SCIENCE

Pancreatic cancer is typically diagnosed late, leading to low survival rates. Our proprietary detection method leverages **cfDNA liquid biopsy** and **DNA methylation analysis** to identify tumor-derived cancer markers in the bloodstream early, with high sensitivity and precision - even before symptoms emerge.

## KEY BENEFITS

- **Non-Invasive** – Requires only a blood sample; no traditional biopsy needed
- **High Sensitivity** – Taiwan + Western Cohort Stage I&II 93.8%, Stage III & IV 100% sensitivity in preclinical studies
- **Fast Results** – Rapid turnaround supports prompt medical action
- **Cost-Effective** – Lower cost compared to imaging or invasive diagnostic methods
- **Reliable & Reproducible** – Built on validated methylation and biomarker technology

## TARGET MARKET

- **High-Risk Patient Populations** – Individuals with family history or chronic risk factors like diabetes
- **Healthcare Providers & Oncologists** – Seeking better early detection tools
- **Biotech & Pharma Companies** – Engaged in cancer trials and diagnostics
- **Clinical & Diagnostic Labs** – Offering advanced oncology testing services

## STATUS & VISION

Pancreatic cancer blood test offered as a Laboratory Developed Test (LDT) through our CAP-accredited, CLIA-certified laboratory.

## CLINICAL TRIAL STATUS

Recruitment for 100 pancreatic cancer patients + 400 high risk subjects underway to be completed by Q4 2025  
FDA Breakthrough Device Designation application to be submitted by December 2025



# Breast Cancer Monitoring

The EG-Breast Blood Test-P1 is a non-invasive, blood-based diagnostic that leverages DNA methylation analysis to monitor breast cancer progression during and after treatment, addressing the critical need for continuous, real-time insights into treatment response and recurrence risk, without relying on invasive procedures or delayed imaging.

## THE SCIENCE

Breast cancer remains the most common cancer in women, with up to 30%<sup>1</sup> of early-stage patients developing metastases that drive most cancer-related deaths. Conventional biomarkers like CA15-3 and CEA detect only 60–80%<sup>2</sup> of cases, limiting their reliability.

Circulating methylated GCM2 and TMEM240 have emerged as potential biomarkers. Their methylation levels mirror treatment response and tumor burden, offering a noninvasive, real-time tool for monitoring disease progression and guiding clinical decisions.

## KEY BENEFITS

- **Non-Invasive Monitoring** – Blood-based test eliminates the need for traditional invasive monitoring
- **Real-Time Insights** – Enables continuous tracking of patient status throughout treatment and recovery
- **Tailored Follow-Up** – Supports more personalized treatment decisions based on patient-specific biomarker response

## TARGET MARKET

- **Breast Cancer Patients** – Undergoing treatment or in remission
- **Healthcare Providers** – Needing a reliable, non-invasive method to monitor disease status
- **Oncologists & Specialists** – Focused on long-term follow-up and personalized care

## STATUS & VISION

Currently in clinical trials with promising preclinical results.

Planned to release LDT in the U.S. market by November 2025.



Source | 1,2. "Monitoring breast cancer progression through circulating methylated GCM2 and TMEM240 detection, 2025

# Our Comprehensive Coverage

Our Seattle area, WA laboratory is approved and certified to provide testing to majority of the U.S. market with full U.S. coverage to be achieved by 2026.

## Effective: January 2025

Scope: Can collect blood samples and offer testing in 41 U.S. states, including:

CA, WA, AL, AK, AZ, AR, CO, CT, DE, DC, FL, GA, GU, HI, ID, IL, IN, IA, KS, KY, LA, ME, MA, MI, MO, MT, NE, NV, NH, NM, NC, ND, OH, OK, SC, SD, TN, TX, UT, VT, VA, WV, WI, WY

## Optional/Conditional


NJ, MN, NV, OR, MS

## Effective: November 2025

Maryland, Pennsylvania, Rhode Island

## Effective: July 2026

New York



# Eye Care

Our Exovisse artificial tear formulation is designed to relieve symptoms of dry eye disease by restoring moisture and improving ocular comfort, providing safe, non-invasive relief for patients with sensitive or irritated eyes.

## THE SCIENCE

Millions of people experience symptoms of eye dryness. This drop-based solution provides gentle hydration and protection for everyday use. By helping to relieve dryness and protect against further irritation, the drops reduce discomfort caused by minor eye irritation or exposure to wind and sun.

## KEY BENEFITS

- **Moisture Restoration** – Rehydrates and lubricates for long-lasting comfort
- **Soothing Relief** – Reduces irritation, burning, and gritty sensations
- **Non-Invasive & Easy to Use** – Drop-based format, suitable for daily use
- **Ocular Safety** – Formulated for sensitive eyes, including contact lens users

## TARGET MARKET

- **Patients with Dry Eye Disease** – Especially those with chronic or severe symptoms
- **Individuals with Ocular Surface Damage** – Caused by environmental stress, screen exposure, or lens use
- **Ophthalmologists & Eye Care Providers** – Recommending supportive care for dry eye conditions
- **People with Sensitive Eyes** – Including contact lens wearers or those in dry/air-conditioned environments

## STATUS & VISION

Formulated in compliance with FDA OTC Monograph M018 requirements. Poised to meet the growing demand for safe, effective, and accessible eye care solutions worldwide.



# Contact Lenses

Exovisse is a next-generation hydrogel and silicone hydrogel contact lens designed to improve daily comfort and wearability. It is engineered to provide consistent performance throughout the day, even in situations where traditional lenses may feel less comfortable.

## THE SCIENCE

Exovisse uses an advanced hydrogel matrix that helps retain moisture and maintain lens hydration throughout the day. The lens is designed for high tolerability and consistent comfort, making it suitable for daily wear.

## KEY BENEFITS

- **Improved Comfort** – Designed for sensitive eyes to minimize irritation and enhance wearability
- **Sustained Hydration** – Hydrogel matrix retains moisture and reduces dryness
- **Convenient Wear** – Daily-wear format ideal for everyday use and long-term compliance
- **Quality** – FDA-cleared Class II medical device with proven safety and efficacy

## TARGET MARKET

- **Contact Lens Users** – Experiencing dryness, discomfort, or irritation
- **Patients with Chronic Eye Conditions** – Including dry eye disease and corneal damage
- **Eye Care Providers** – Ophthalmologists and optometrists seeking safe, effective solutions
- **Comfort-Seeking Consumers** – Those needing gentle, comfortable lenses for everyday use

## STATUS & VISION

Exovisse is **FDA-cleared as a 510(k) K213119 Class II medical device** and is **commercially available** for global distribution. It offers a differentiated solution in the fast-growing vision care market, with strong adoption potential among eye care professionals and patients alike.



# Eye Tissue Regeneration

YD Bio's investigational **limbal stem cell (LSC) exosome injection and eye drops** are a targeted therapy for patients with treatment-resistant ocular conditions. Designed to promote **tissue repair**, reduce **inflammation**, and support the healing of **chronic or severe eye diseases**, these products offer a next-generation approach beyond standard treatments.

## THE SCIENCE

The therapy delivers therapeutic agents directly to the **corneal surface** and **ocular microenvironment**, using exosomes derived from limbal stem cells. This targeted delivery allows for localized action at the site of inflammation or damage, accelerating tissue recovery where systemic treatments fall short.

## POTENTIAL BENEFITS

- **Targeted Delivery** – Delivered to affected tissue for maximum therapeutic impact
- **Anti-Inflammatory Action** – Reduces local inflammation and irritation in resistant cases
- **Tissue Repair** – Promotes regeneration of corneal and conjunctival tissue
- **Long-Lasting Effect** – Delivers sustained benefits

## POTENTIAL MARKET

- **Patients with Severe Dry Eye or Chronic Inflammation** – Unresponsive to standard care
- **Individuals with Corneal Damage** – Including post-surgical recovery or trauma
- **Ophthalmologists and Eye Specialists** – Seeking advanced, non-surgical solutions
- **Patients Seeking Regenerative Therapy** – For long-term eye health and repair

## STATUS & VISION

Currently in **clinical development**, with promising results in pre-clinical trials in inflammation reduction and tissue regeneration.

Phase 1 clinical trials to be completed in 2027, Phase 2 in 2029 and Phase 3 in 2032, positioning this therapy as a breakthrough solution in ocular health and regenerative medicine.



# Health Supplements

Our precision supplements, currently sold in Asia, target specific nutritional gaps to support immunity, energy, and overall wellness, helping the body function at its best.

## TARGET MARKET

Supplements represent a growth opportunity by serving diverse, health-conscious consumers, aligning with global wellness trends, benefiting from streamlined distribution channels, and leveraging YD Bio's strong in-house formulation and development expertise



Natural  
Ingredients



Targeted  
Formulations



Backed by  
Science



High-Quality  
Standards



Multi-Segment  
Target Opportunity



Large & Growing  
Market Size

## STATUS & VISION

Currently available for distribution outside the U.S with a strong presence in global markets.

We are actively formulating new supplements specifically designed for the US market.



# Clinical Trial Drug Distribution

YD Bio provides end-to-end sourcing and compliant distribution of clinical trial drugs to leading pharmaceutical, biotech, and research organizations worldwide.

## TARGET MARKET

Clinical trial drug services support a wide range of global partners, from major pharmaceutical companies to CROs and academic research institutions, all seeking reliable, GMP-compliant sourcing and distribution across multiple regions.



**Reliable  
Supply**



**Global  
Reach**



**High-Quality  
Standards**



**Tailored  
Solutions**




**Trusted by  
Industry Leaders**

## STATUS & VISION

Currently operational and supplying global clinical trials across multiple regions.

YD Bio is scaling its distribution platform to support growing demand and enable new research partnerships around the world.



# Our Leadership Team

Our leadership team combines deep scientific expertise, global industry experience, and academic excellence from top institutions - united by a shared commitment to innovation and patient impact.



**Ethan Shen, PhD**  
Chairman/CEO

Ph.D. of Translational Medicine, Academia Sinica and Taipei Medical University, Taipei, Taiwan

Graduate Certificate in Financial Management  
Baruch College/ New York

EMBA, FUDAN University and National Taiwan University

**Expertise:**

Translational Medicine  
New drug development  
Medical-grade health product development  
Financial Management



**Edmund Hen, MSc, FCA, CPA**  
CFO

Master of Science in Professional Accounting University  
College London, UK

Bachelor of Science in Accounting and Finance  
University of East Anglia, UK

**Expertise:**

Corporate Financial Management  
Capital Market Operations  
International Accounting and Audit Experience  
Financial Strategy and Fundraising  
Internal Controls and Compliance



**Benjamin Zhang, MD**  
CMO

School of Medicine, Taipei Medical University, Taipei, Taiwan

**Expertise:**

Cell Engineering  
GMP-grade Cell Manufacturing  
IND Submission Clinical Trial Translational  
Medicine  
New Drug Development

# We Are Targeting Large Global Markets With Urgent Needs

With leading solutions in both cancer diagnostics and ocular health, YD Bio is positioned to scale in two multi-billion-dollar global markets driven by innovation, demand, and clinical need.

## Cancer Diagnostics

**\$178B**

Global Market by 2033

**CAGR: 5.91%<sup>1</sup>**

**\$59B**

US Market by 2030

**CAGR: 6.4%<sup>2</sup>**

- Rising demand for early, non-invasive cancer detection
- Strong momentum in liquid biopsy and AI-powered diagnostics
- High-impact submarkets:

### Pancreatic Cancer

**G - \$4.7B by 2030<sup>5</sup>**

**US - \$2.4 by 2033<sup>5</sup>**

### Breast Cancer

**G - \$9.5B by 2034<sup>6</sup>**

**US - \$3B by 2033<sup>9</sup>**

## Eye Health

Contact Lens

**\$26.5B**

Global Market by 2033

**CAGR: 5.0%<sup>3</sup>**

**\$9.2B**

US Market by 2033

**CAGR: 3.8%<sup>4</sup>**

- 140M+ global lens users, 1.4B dry eye patients
- Rapid growth in dry eye and glaucoma treatment
- Strong demand for non-invasive, effective ocular therapies

### Dry Eye Market

**G - \$13B by 2032<sup>7</sup>**

**US - \$4.8B by 2030<sup>10</sup>**

### Glaucoma Market


**G - \$8.5B by 2030<sup>8</sup>**

**US - \$3.7B by 2033<sup>11</sup>**

# Financials

## Net Revenue (\$) by sales categories


Fiscal Years Ended December 31, 2023 and 2024



For the year ended December 31, 2024, revenue was derived primarily from the sale of medical and related products, which accounted for 57.4%. Sales of drugs contributed 28.1%, nutritional products made up 8.2%, and supplements accounted for the remaining 6.3% of total revenue.

## Net Revenue (\$)

Fiscal Years Ended December 31, 2023 and 2024 (in thousands)




Net revenue increased by \$160,229 or 46% from \$350,131 for the year ended December 31, 2023, compared to \$510,360 for the year ended December 31, 2024. The revenue for the year arises from the sales of drugs, medical and related products, nutritional and supplements products in Taiwan.


# Financials

## Gross Profit (\$)

Fiscal Years Ended December 31, 2023 and 2024 (in thousands)



For the years ended December 31, 2023 and 2024, gross profits were \$153,000 and \$155,000, respectively. Our gross profit increased by \$2,000, or approximately 1.3% primarily due to the increase in sales demand of the medical and related products and drugs.



# Shaping the Future of Patient Care

**Transformative science, trusted partnerships, and scalable growth in high-impact healthy markets.**

## **Market Potential**

Multi-billion-dollar cancer diagnostics & ocular health markets

## **Breakthrough Science**

Innovative diagnostic & regenerative medicine platforms

## **Strategic Partnerships**


20-year exclusive agreements with leading biotech innovators

## **Proven Execution**

Track record in pharma alliances & global commercialization

## **Scalable Growth**

Continued innovation pipeline & diversified revenue streams





# Thank You

For investor inquiries, please contact: [investor@ydesgroup.com](mailto:investor@ydesgroup.com)

**Investor Relations**

WFS Investor Relations Inc. (WFS)  
[services@wealthfslc.com](mailto:services@wealthfslc.com)

Auditor: ARK Pro CPA & Co

Legal Counsel: Winston & Strawn, LLP

**ydbio**

[ydesgroup.com](http://ydesgroup.com)